• DLBCL: outcomes in patients with R-CHOP with/without consolidation RT

    No significant difference in 5-year survival.

  • Follicular lymphoma: short-course BR followed by 90YIT consolidation delivers high, durable response

    90YIT consolidation realized impressive PR to CR/CRu conversion.

  • DLBCL with CNS involvement: RCHOP-HD MTX extends remission

    No significant benefit with consolidation auto-SCT.

  • Brentuximab+AVD delivers excellent response in early nonbulky cHL

    Most patients required only 4 cycles of chemotherapy.

  • EHA 2019 – Nelarabine in the real-world, an effective option for relapsed/refractory T-acute lymphoblastic leukaemia/lymphoma

    In one of the largest cohorts of adult patients with the disease, nelarabine led to good response rates and was shown effective in bridging patients to transplant

  • EHA 2019 – Induction with obinutuzumab plus DHAP in mantle cell lymphoma leads to a high level of minimal residual disease negativity

    In the LYMA-101 trial, 75% of previously untreated patients reached the minimal residual disease negativity after this regimen, without major toxicity

  • EHA 2019 – Durable benefits with brentuximab vedotin plus chemotherapy as frontline treatment in classical Hodgkin lymphoma

    According to the 3-year update of ECHELON-1 trial, A+AVD compares favourably with ABVD in patients with stage III/IV disease, independently of PET2 status

  • FDA approves polatuzumab vedotin combo for DLBCL

    Indicated with bendamustine and rituximab after failure of 2 or more prior therapies.

  • Guidelines for breast implant-associated anaplastic large-cell lymphoma

    Guidelines prepared by the UK National Co-ordinating Committee of Breast Pathology.

  • Peripheral T-cell lymphoma: bendamustine combo delivers high, durable remission

    ASCT further delayed progression in this phase 2 trial.

  • DLBCL: lymphoma-related hypercalcemia linked to inferior survival

    The association did not apply to hyperparathyroidism-related hypercalcemia.

  • Pooled analysis nixes link between blood transfusions, NHL

    Data from 10,805 NHL cases and 14,026 controls contradict earlier meta-analysis.

  • ASCO 2019 — Extended ibrutinib therapy maintains long-term advantage in CLL

    6-year follow-up of the phase 3 RESONATE trial.

  • ASCO 2019 — Lenalidomide-rituximab yields high response rate in relapsed/refractory FL, MZL

    Combination was approved by FDA on May 28, 2019.

  • Load more